TVARDI THERAPEUTICS, INC. Payments of Merger Related Costs, Financing Activities
TVARDI THERAPEUTICS, INC. (TVRD) reported Payments of Merger Related Costs, Financing Activities of $2.82 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. payments of merger related costs, financing activities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- TVARDI THERAPEUTICS, INC. payments of merger related costs, financing activities for the quarter ending 2025-09-30 was $429.00K.
- TVARDI THERAPEUTICS, INC. payments of merger related costs, financing activities for the quarter ending 2025-06-30 was $786.00K.
- TVARDI THERAPEUTICS, INC. payments of merger related costs, financing activities for the quarter ending 2025-03-31 was $1.61M.
- TVARDI THERAPEUTICS, INC. payments of merger related costs, financing activities for fiscal 2025 was $2.82M, a 116.50% increase from fiscal 2024.
- TVARDI THERAPEUTICS, INC. payments of merger related costs, financing activities for fiscal 2024 was $1.30M.
| Period end | Payments of Merger Related Costs, Financing Activities 3 month | Payments of Merger Related Costs, Financing Activities 6 month | Payments of Merger Related Costs, Financing Activities 9 month | Payments of Merger Related Costs, Financing Activities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $429.00K derived: sum of 2 quarters · filed 2026-03-31 | $1.22M derived: sum of 3 quarters · filed 2026-08-14 | $2.82M 10-K · filed 2026-03-31 |
| 2025-09-30 | $429.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.22M derived: sum of 2 quarters · filed 2026-08-14 | $2.82M 10-Q · filed 2025-11-13 | $4.11M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $786.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.39M 10-Q · filed 2026-08-14 | $3.68M derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-03-31 | $1.61M 10-Q · filed 2026-05-08 | $2.90M derived: sum of 2 quarters · filed 2026-05-08 | ||
| 2024-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.30M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $14.00K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |